Navigation Links
FDA Gives Approval for Skin Cancer Drug, Zolinza

Zolinza, the most recent skin cancer drug has today received approval from the U.S. Food and Drug Administration (FDA). Zolinza (vorinostat) capsules is mainly recommended// for the treatment of cutaneous T-cell lymphoma (CTCL) type of skin cancer when the disease persists, worsens, or returns during or after treatment with other medicines.

Zolinza has been approved as part of FDA's Orphan Drug program that offers companies financial incentives to develop medications for diseases which affect less than 200,000 American patients a year. About three in every one million people are diagnosed with CTCL each year in the United States. Most of those afflicted with CTCL are men with an average age of 50 years.

Steven Galson, M.D., director of FDA's Center for Drug Evaluation and Research said, "This approval is another example of the benefits of modern research that's focused on providing prescribers with safe and effective therapies for all types of cancer, including those that affect relatively few patients."

Two clinical trials that were conducted with 107 CTCL patients gave evidence of Zolinza's safety and effectiveness. These patients were treated with Zolinza following return of their disease following other treatments.

30 percent of patients who received Zolinza observed an improvement in a scale that was defined by scoring of skin lesions and lasted an average of 168 days.

Some of the most common serious adverse events that occurred were pulmonary embolism, deep vein thrombosis, dehydration, and anemia. Some of most common other adverse events were gastrointestinal symptoms such as nausea, diarrhea, vomiting, anorexia and constipation; fatigue; chills; and taste disorders.

However Zolinza has shown probable fetal harm if administered during pregnancy according to results of animal studies.

Zolinza is manufactured by Pantheon, Inc., in Mississauga, Ontario, Canada, for Merck & Co., Inc., Whitehouse Station, N.J.
NLA
'"/>




Related medicine news :

1. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
2. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
3. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
4. US Doctors Association Gives away $110,000 To NGO’
5. Woman In Coma Gives Birth To Daughter
6. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
7. New Eye Surgery Gives Hope To Short-Sighted
8. Jharkhand Gives Health industry status
9. WHO Gives Its Approval For Bird Flu Test Kit
10. FDA Gives Its Approval For Inhaler
11. Congestion for Use of Clarinex-D 12 Hour cleared – FDA Gives the No
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination ... and concern over nerve agents and the deadly use of chemical weapons. Many questions ... and how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based in ... Palo Alto, is proud to announce an important upgrade to its geographic information pages, ... care close to home, and by having city-specific pages, NuevaCare is answering that information ...
(Date:2/26/2017)... KS (PRWEB) , ... February ... ... StaffBridge sets a new technology standard in staffing, scheduling, and reporting for ... monitor, and predict activity throughout the entire staffing process. StaffBridge technology improves ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... (PD) in persons with a specific LRRK2 mutation, according to a study released ... studies have provided evidence of a link between pesticides and incidence of sporadic ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist ... his office, Antoine Dental Center. Currently, patients can get single dental implants for ... but patients can learn more about these offers by contacting Antoine Dental Center. ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... NEW YORK , Feb. 27, 2017 ... Michael P. Vallely , MBBS, PhD, ... the University of Sydney will be ...  Journal of the American College of ... newer "no-touch" beating heart bypass surgery technique ...
(Date:2/27/2017)... TAMPA, Fla. , Feb. 27, 2017 /PRNewswire/ ... company focused on developing cerebral embolic protection devices ... of the FDA,s Circulatory System Devices Panel that ... the need for cerebral protection following transcatheter aortic ... shared by this FDA panel support the need ...
(Date:2/27/2017)... , February 27, 2017 Now ... the pharmaceutical companies that are most successful at developing and ... ... you gave the same molecule to two different companies in ... Based on systematic, objective analysis of each company,s performance ...
Breaking Medicine Technology: